Zardaverine 16 (Figure 5) was originally reported in 1984, as a dual PDE3/PDE4 inhibitor for the treatment of asthma, demonstrating to inhibit bronchoconstriction events more effectively than theophylline [59]. Here, PDE4A is linked to asthma.